Browsing by Author Gouva, C.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 2 to 8 of 8 < previous 
TitleAuthor(s)Issue date???itemlist.???
Epoetin alpha increases plasma HDL levels and HDL-associated PAF-acetylhydrolase activity in patients with chronic renal failurePapavasiliou, E. C.; Gouva, C.; Siamopoulos, K. C.; Tselepis, A. D.24-Nov-2015-
Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: Effect of long-term therapy with erythropoietinPapavasiliou, E. C.; Gouva, C.; Siamopoulos, K. C.; Tselepis, A. D.24-Nov-2015-
Erythropoietin administration in patients with chronic renal failure prevents the decrease in RBC-associated antioxidant enzyme activitiesPapavasiliou, E. C.; Gouva, C.; Katopodis, K. P.; Nikolopoulos, P.; Tselepis, A. D.; Siamopoulos, K. C.24-Nov-2015-
Increase of HDL-associated platelet-activating-factor acetylhydrolase (PAF-AH) activity but not of paraoxonase (PON1) during haemodialysisLiberopoulos, E.; Papavasiliou, E.; Tzallas, C.; Katopodis, K.; Gouva, C.; Christidis, D.; Tselepis, A.; Siamopoulos, K.; Elisaf, M.24-Nov-2015-
Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKDSiamopoulos, K. C.; Gouva, C.; Katopodis, K. P.; Tzallas, C.; Nikolopoulos, P.; Papavasiliou, E. C.; Tselepis, A. D.24-Nov-2015-
PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietinPapavasiliou, E. C.; Gouva, C.; Siamopoulos, K. C.; Tselepis, A. D.24-Nov-2015-
Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trialGouva, C.; Nikolopoulos, P.; Ioannidis, J. P.; Siamopoulos, K. C.24-Nov-2015-